Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients

Genes Chromosomes and Cancer

Volumn 52, Issue 9, 2013, Pages 794-801

  Pedersen, Brent S ^a   Konstantinopoulos, Panagiotis A ^b   Spillman, Monique A ^a   De, Subhajyoti ^a,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; MRE11A PROTEIN; NUCLEIC ACID BINDING PROTEIN; RAD50 PROTEIN; RAD52 PROTEIN; UNCLASSIFIED DRUG; XRCC2 PROTEIN; XRCC3 PROTEIN;

ADULT; AGED; AGING; ARTICLE; CHROMOSOME 13; CHROMOSOME 17; CONTROLLED STUDY; DNA REPAIR; FEMALE; GENE EXPRESSION; GENE LOCUS; GERM LINE; HETEROZYGOSITY LOSS; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

ADULT; AGED; AGED, 80 AND OVER; AGING; CYSTADENOCARCINOMA, SEROUS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HOMOLOGOUS RECOMBINATION; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 84880506377     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22075     Document Type: Article

References (34)

1. Bahar R, Hartmann CH, Rodriguez KA, Denny AD, Busuttil RA, Dolle ME, Calder RB, Chisholm GB, Pollock BH, Klein CA, Vijg J. 2006. Increased cell-to-cell variation in gene expression in ageing mouse heart. Nature 441:1011-1014.
2. Balducci L, Corcoran MB. 2000. Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am 14:193-212.
3. Carr LL, Gottschling DE. 2008. Does age influence loss of heterozygosity? Exp Gerontol 43:123-129.
4. Chapman JR, Taylor MR, Boulton SJ. 2012. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell 47:497-510.
5. Chen JH, Hales CN, Ozanne SE. 2007. DNA damage, cellular senescence and organismal ageing: Causal or correlative? Nucleic Acids Res 35:7417-7428.
6. Cluett C, Melzer D. 2009. Human genetic variations: Beacons on the pathways to successful ageing. Mech Ageing Dev 130:553-563.
7. De S. 2011. Somatic mosaicism in healthy human tissues. Trends Genet 27:217-223.
8. De S, Babu MM. 2010. A time-invariant principle of genome evolution. Proc Natl Acad Sci U S A 107:13004-13009.
9. De S, Lopez-Bigas N, Teichmann SA. 2008. Patterns of evolutionary constraints on genes in humans. BMC Evol Biol 8:275.
10. Eccles DM, Russell SE, Haites NE, Atkinson R, Bell DW, Gruber L, Hickey I, Kelly K, Kitchener H, Leonard R. 1992. Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group. Oncogene 7:2069-2072.
11. Eissenberg JC. 2013. Telomeres, cancer & aging: Live long & prosper? Mo Med 110:11-16.
12. Engels WR, Johnson-Schlitz D, Flores C, White L, Preston CR. 2007. A third link connecting aging with double strand break repair. Cell Cycle 6:131-135.
13. Garcia A, Bussaglia E, Machin P, Matias-Guiu X, Prat J. 2000. Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: Association with carcinomas with serous differentiation. Int J Gynecol Pathol 19:152-157.
14. Glaab E, Schneider R. 2012. PathVar: Analysis of gene and protein expression variance in cellular pathways using microarray data. Bioinformatics 28:446-447.
15. Jemal A, Siegel R, Xu J, Ward E. 2010. Cancer statistics, 2010. CA Cancer J Clin 60:277-300.
16. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de Sauvage FJ, Faham M, Seshagiri S. 2010. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466:869-873.
17. Kirkwood TB. 2005. Understanding the odd science of aging. Cell 120:437-447.
18. McMurray MA, Gottschling DE. 2003. An age-induced switch to a hyper-recombinational state. Science 301:1908-1911.
19. Moragoda L, Jaszewski R, Kulkarni P, Majumdar AP. 2002. Age-associated loss of heterozygosity of tumor suppressor genes in the gastric mucosa of humans. Am J Physiol Gastrointest Liver Physiol 282(6):G932-G936.
20. Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F, Webb PM. 2007. Obesity and the risk of epithelial ovarian cancer: A systematic review and meta-analysis. Eur J Cancer 43:690-709.
21. Pignata S, Vermorken JB. 2004. Ovarian cancer in the elderly. Crit Rev Oncol Hematol 49:77-86.
22. Preston CR, Flores C, Engels WR. 2006. Age-dependent usage of double-strand-break repair pathways. Curr Biol 16:2009-2015.
23. Ries LA. 1993. Ovarian cancer. Survival and treatment differences by age. Cancer 71:524-529.
24. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J. 2007. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program:NIH Pub. No. 07-6215.
25. Riggs JE. 1995. Rising ovarian cancer mortality in the elderly: A manifestation of differential survival. Gynecol Oncol 58:64-67.
26. Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, Rodrigues DN, Renwick A, Seal S, Ramsay E, Duarte Sdel V, Rivas MA, Warren-Perry M, Zachariou A, Campion-Flora A, Hanks S, Murray A, Pour NA, Douglas J, Gregory L, Rimmer A, Walker NM, Yang TP, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Eccles D, Evans DG, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L, Gore M, Houlston R, Brown MA, Caufield MJ, Deloukas P, McCarthy MI, Todd JA, Turnbull C, Reis-Filho JS, Ashworth A, Antoniou AC, Lord CJ, Donnelly P, Rahman N. 2013. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 493:406-410.
27. Schwarzenbach H, Eichelser C, Kropidlowski J, Janni W, Rack B, Pantel K. 2012. Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression. Clin Cancer Res 18:5719-5730.
28. Sekine M, Yoshihara K, Komata D, Haino K, Nishino K, Tanaka K. 2013. Increased incidence of brain metastases in BRCA1-related ovarian cancers. J Obstet Gynaecol Res 39:292-296.
29. Seluanov A, Mittelman D, Pereira-Smith OM, Wilson JH, Gorbunova V. 2004. DNA end joining becomes less efficient and more error-prone during cellular senescence. Proc Natl Acad Sci U S A 101:7624-7629.
30. TCGA. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-1068.
31. TCGA. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615.
32. Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, Dickler M, Robson M, Moy F, Goswami S, Oktay K. 2013. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med 5:172ra121.
33. Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, DeFazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD, Matulonis UA. 2012. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 18:5806-5815.
34. Yancik R. 1993. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71:517-523.